Bank of America Lowers United Therapeutics (NASDAQ:UTHR) Price Target to $315.00

United Therapeutics (NASDAQ:UTHR - Free Report) had its price target cut by Bank of America from $321.00 to $315.00 in a report issued on Wednesday,Benzinga reports. They currently have a neutral rating on the biotechnology company's stock.

UTHR has been the topic of several other reports. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. cut their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald assumed coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $393.08.

United Therapeutics Trading Down 0.5%

Shares of United Therapeutics stock traded down $1.38 during trading on Wednesday, reaching $284.77. The stock had a trading volume of 197,200 shares, compared to its average volume of 451,328. The company has a market capitalization of $12.84 billion, a price-to-earnings ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.57. The stock has a fifty day moving average price of $300.43 and a two-hundred day moving average price of $331.51. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $6.17 EPS. On average, equities analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at $10,437,712.18. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total value of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,500 shares of company stock worth $20,828,390. 10.30% of the stock is currently owned by corporate insiders.

Institutional Trading of United Therapeutics

Several large investors have recently bought and sold shares of the business. Acadian Asset Management LLC lifted its holdings in shares of United Therapeutics by 1,657.8% in the first quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company's stock worth $55,217,000 after acquiring an additional 169,010 shares during the last quarter. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Intech Investment Management LLC lifted its stake in United Therapeutics by 1.4% in the 1st quarter. Intech Investment Management LLC now owns 30,935 shares of the biotechnology company's stock valued at $9,536,000 after purchasing an additional 442 shares during the last quarter. Capital Impact Advisors LLC bought a new position in United Therapeutics in the 1st quarter valued at approximately $6,508,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in United Therapeutics by 10.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 257,662 shares of the biotechnology company's stock valued at $79,429,000 after buying an additional 25,289 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.